The role of CD47 in non-neoplastic diseases

Chao Wang; Ying Feng; Deepali Patel; Hongwei Xie; Yaqing Lv; Hai Zhao

doi:10.1016/j.heliyon.2023.e22905

The role of CD47 in non-neoplastic diseases

Heliyon. 2023 Nov 29;9(12):e22905. doi: 10.1016/j.heliyon.2023.e22905. eCollection 2023 Dec.

Authors

Chao Wang¹, Ying Feng², Deepali Patel³, Hongwei Xie¹, Yaqing Lv⁴, Hai Zhao¹

Affiliations

¹ Department of Neurosurgery, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, China.
² Department of Emergency, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, China.
³ School of Medicine, Qingdao University, No. 308 Ningxia Road, Qingdao, Shandong, 266071, China.
⁴ Department of Outpatient, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, China.

Abstract

CD47 is a 50 kDa five-spanning membrane receptor that plays a crucial role in multiple cellular processes, including myeloid cell activation, neutrophils transmigration, vascular remodeling, leukocyte adhesion and trans-endothelial migration. Recent studies have revealed that CD47 is a highly expressed anti-phagocytic signal in several types of cancer, and therefore, blocking of CD47 has shown an effective therapeutic potential in cancer immunotherapy. In addition, CD47 has been found to be involved in a complex interplay with microglia and other types of cells, and increasing evidence indicates that CD47 can be targeted as part of immune modulatory strategies for non-neoplastic diseases as well. In this review, we focus on CD47 and its role in non-neoplastic diseases, including neurological disorders, atherosclerosis and autoimmune diseases. In addition, we discuss the major challenges and potential remedies associated with CD47-SIRPα-based immunotherapies.

Keywords: Atherosclerosis; Autoimmune diseases; CD47; Immune modulation; Immunotherapies; Neurological disorders; SIRPα.

Publication types

Review